Honokiol: A non-adipogenic PPARγ agonist from nature

Atanasov, Atanas G.; Wang, Jian N.; Gu, Shi P.; Bu, Jing; Kramer, Matthias P.; Baumgartner, Lisa; Fakhrudin, Nanang; Ladurner, Angela; Malainer, Clemens; Vuorinen, Anna-Leena; Noha, Stefan M.; Schwaiger, Stefan; Rollinger, Judith M.; Schuster, Daniela; Stuppner, Hermann; Dirsch, Verena M.; Heiss, Elke H.

doi:10.1016/j.bbagen.2013.06.021

Cited by 123 publications

(108 citation statements)

References 33 publications

Supporting

Mentioning

103

Contrasting

Order By: Relevance

“…Recent study shows that honokiol is a promising lead to bind the peroxisome proliferator-activated receptor gamma (Atanasov et al 2013) and stimulate basal glucose uptake in differentiated adipocytes. Interestingly, at least three glucose transmembrane transporters (Ght1, Ght2 and Ght4) are up-regulated by honokiol treatment in fission yeast (Figure 3), which implies that the improvement of sugar uptake and potential faster glycolysis rate is a common honokiol’s MoA within both yeast and mammalian cells.…”

Section: Discussionmentioning

confidence: 99%

Antifungal compound honokiol triggers oxidative stress responsive signalling pathway and modulates central carbon metabolism

Wang

Yan

2016

Mycology

View full text Add to dashboard Cite

The fast growing evidences have shown that the plant-derived compound honokiol is a promising candidate for treating multiple human diseases, such as inflammation and cancer. However, the mode-of-action (MoA) of honokiol remains largely unclear. Here, we studied the antifungal activity of honokiol in fission yeast model, with the goal of understanding the honokiol’s mechanism of action from the molecular level. We found that honokiol can inhibit the yeast growth at a dose-dependent way. Microarray analysis showed that honokiol has wide impacts on the fission yeast transcription levels (in total, 512 genes are up-regulated, and 42 genes are down-regulated). Gene set enrichment analysis indicated that over 45% up-regulated genes belong to the core environmental stress responses category. Moreover, network analysis suggested that there are extensive gene–gene interactions amongst the co-expression gene lists, which can assemble several biofunctionally important modules. It is noteworthy that several key components of central carbon metabolism, such as glucose transporters and metabolic enzymes of glycolysis, are involved in honokiol’s MoA. The complexity of the honokiol’s MoA displayed in previous studies and this work demonstrates that multiple omics approaches and bioinformatics tools should be applied together to achieve the complete scenario of honokiol’s antifungal function.

show abstract

Section: Discussionmentioning

confidence: 99%

Antifungal compound honokiol triggers oxidative stress responsive signalling pathway and modulates central carbon metabolism

Wang

Yan

2016

Mycology

View full text Add to dashboard Cite

show abstract

“…These results merit the study of the potential antidiabetic mechanism(s) of these species. In a search for a natural PPAR-γ agonist, Atanasov et al [110] reported that the natural product honokiol from the traditional Chinese herbal drug Magnolia bark stimulates the basal glucose uptake in a comparable pattern to pioglitazone, but without inducing adipogenesis.…”

Section: Activation Of the Nuclear Receptor Ppar-γmentioning

confidence: 99%

Phytotherapy in diabetes: Review on potential mechanistic perspectives

El‐Abhar

Schaalan

2014

WJD

108

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a widely spread epidemic disease that results from the absence of insulin, decreased secretion and/or impaired function. Since DM is a multifactorial disease, the available pharmaceuticals, despite their sensible treatment, target mostly one pathway to control hyperglycemia and encounter several side effects. Therefore, new therapeutic paradigms aim to hit several pathways using only one agent. Traditionally, antidiabetic plants and/or their active constituents may fulfill this need. More than 200 species of plants possess antidiabetic properties which were evaluated mostly by screening tests without digging far for the exact mode of action. Searching among the different literature resources and various database and in view of the above aspects, the present article provides a comprehensive review on the available antidiabetic plants that have been approved by pharmacological and clinical evaluations, and which their mechanism(s) of action is assured. These plants are categorized according to their proved mode of action and are classified into those that act by inhibiting glucose absorption from intestine, increasing insulin secretion from the pancreas, inhibiting glucose production from hepatocytes, or enhancing glucose uptake by adipose and muscle tissues. The current review also highlights those that mimic in their action the new peptide analogs, such as exenatide, liraglutide and dipeptidylpeptidase-4 inhibitors that increase glucagon-like peptide-1 serum concentration and slow down the gastric emptying.© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.Key words: Hypoglycaemic nutraceuticals; Antidiabetic phyto-constituents; Medicinal plants; Phytotherapy; Diabetes mellitus Core tip: Diabetes is a serious metabolic disorder that is currently treated by different types of synthetic oral hypoglycemic agents, in addition to insulin. However, due to the unwanted side effects, the efficacies of these compounds are debatable and there is a demand for new compounds for the treatment of diabetes. Therefore, attention has been directed towards nutraceuticals originating from plants that are rich in antidiabetic phyto-constituents. Although the evidenced-based therapeutic usage of many plants is scarce, the plants cited in this review are those reputed traditionally for their antidiabetic effect and that were verified either experimentally or clinically.El-Abhar HS, Schaalan MF. Phytotherapy in diabetes: Review on potential mechanistic perspectives. World J Diabetes 2014; 5(2): 176-197 Available from:

show abstract

“…The biological activity of these compounds appears to be due to the presence of hydroxyl and allylic groups on a biphenolic moiety [4, 35, 36]. Several previous studies have reported the effects of M. officinalis on the GI tract.…”

Section: Discussionmentioning

confidence: 99%

Magnolia Officinalis Bark Extract Induces Depolarization of Pacemaker Potentials Through M2 and M3 Muscarinic Receptors in Cultured Murine Small Intestine Interstitial Cells of Cajal

Kim¹,

Han

Kim³

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: Magnolia officinalis Rehder and EH Wilson (M. officinalis) are traditional Chinese medicines widely used for gastrointestinal (GI) tract motility disorder in Asian countries. We investigated the effects of an ethanol extract of M. officinalis (MOE) on the pacemaker potentials of cultured interstitial cells of Cajal (ICCs) in vitro and its effects on GI motor functions in vivo. Methods: We isolated ICCs from small intestines, and the whole-cell patch-clamp configuration was used to record the pacemaker potentials in cultured ICCs in vitro. Both gastric emptying (GE) and intestinal transit rates (ITRs) were investigated in normal and GI motility dysfunction (GMD) mice models in vivo. Results: MOE depolarized ICC pacemaker potentials dose-dependently. Pretreatment with methoctramine (a muscarinic M₂ receptor antagonist) and 4-DAMP (a muscarinic M₃ receptor antagonist) inhibited the effects of MOE on the pacemaker potential relative to treatment with MOE alone. In addition, MOE depolarized pacemaker potentials after pretreatment with Y25130 (a 5-HT₃ receptor antagonist), GR113808 (a 5-HT₄ receptor antagonist) or SB269970 (a 5-HT₇ receptor antagonist). However, pretreatment with RS39604 (a 5-HT₄ receptor antagonist) blocked MOE-induced pacemaker potential depolarizations. Intracellular GDPβS inhibited MOE-induced pacemaker potential depolarization, as did pretreatment with Ca²⁺ free solution or thapsigargin. In normal mice, the GE and ITR values were significantly and dose-dependently increased by MOE. In loperamide-and cisplatin-induced GE delay models, MOE administration reversed the GE deficits. The ITRs of the GMD mice were significantly reduced relative to those of normal mice, which were significantly and dose-dependently reversed by MOE. Conclusion: These results suggest that MOE dose-dependently depolarizes ICCs pacemaker potentials through M₂ and M₃ receptors via internal and external Ca²⁺ regulation through G protein pathways in vitro. Moreover, MOE increased GE and ITRs in vivo in normal and GMD mouse models. Taken together, the results of this study show that MOE have the potential for development as a gastroprokinetic agent in GI motility function.

show abstract

Honokiol: A non-adipogenic PPARγ agonist from nature

Cited by 123 publications

References 33 publications

Antifungal compound honokiol triggers oxidative stress responsive signalling pathway and modulates central carbon metabolism

Antifungal compound honokiol triggers oxidative stress responsive signalling pathway and modulates central carbon metabolism

Phytotherapy in diabetes: Review on potential mechanistic perspectives

Magnolia Officinalis Bark Extract Induces Depolarization of Pacemaker Potentials Through M2 and M3 Muscarinic Receptors in Cultured Murine Small Intestine Interstitial Cells of Cajal

Contact Info

Product

Resources

About